We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Corcept Therapeutics Inc | NASDAQ:CORT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.18 | 4.94% | 25.06 | 24.02 | 26.50 | 26.39 | 23.80 | 26.39 | 2,274,450 | 23:59:48 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Longitude Venture Partners L.P. |
2. Issuer Name
and
Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
800 EL CAMINO REAL, SUITE 220, |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
MENLO PARK, CA 94025 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 3/20/2015 | X (2) | 634516 | A | $2.77 | 13145097 | D (1) | |||
Common Stock | 3/20/2015 | S (2) | 300447 | D | $5.85 | 12844650 | D (1) | |||
Common Stock | 3/20/2015 | X (3) | 486443 | A | $2.77 | 13331093 | D (1) | |||
Common Stock | 3/20/2015 | S (3) | 230333 | D | $5.85 | 13100760 | D (1) | |||
Common Stock | 3/20/2015 | X (5) | 9750 | A | $2.77 | 182742 | I | By LCA (4) | ||
Common Stock | 3/20/2015 | S (5) | 4617 | D | $5.85 | 178125 | I | By LCA (4) | ||
Common Stock | 3/24/2015 | X (6) | 1130709 | A | $2.77 | 14231469 | D (1) | |||
Common Stock | 3/24/2015 | S (6) | 554348 | D | $5.65 | 13677121 | D (1) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Warrant (Right to Buy) | $2.77 | 3/20/2015 | X (2) | 634516 | 3/25/2008 | 3/24/2015 | Common Stock | 634516 | $0 | 1130709 | D (1) | ||||
Warrant (Right to Buy) | $2.77 | 3/20/2015 | X (3) | 486443 | 2/6/2009 | 3/24/2015 | Common Stock | 486443 | $0 | 0 | D (1) | ||||
Warrant (Right to Buy) | $2.77 | 3/20/2015 | X (5) | 9750 | 2/6/2009 | 3/24/2015 | Common Stock | 9750 | $0 | 0 | I | By LCA (4) | |||
Warrant (Right to Buy) | $2.77 | 3/24/2015 | X (6) | 1130709 | 3/25/2008 | 3/24/2015 | Common Stock | 1130709 | $0 | 0 | D (1) |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Longitude Venture Partners L.P.
800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 |
X | X |
|
|
|
Longitude Capital Associates, L.P.
800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 |
|
X |
|
|
|
Longitude Capital Partners, LLC
800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 |
|
X |
|
|
|
Tammenoms Bakker Juliet
C/O LONGITUDE CAPITAL PARTNERS, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 |
|
X |
|
|
Signatures
|
||
/s/ Juliet Tammenoms Bakker, as managing member ofLongitude Capital Partners, LLC, as general partner ofLongitude Venture Partners, L.P | 3/24/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Juliet Tammenoms Bakker, as managing member ofLongitude Capital Partners, LLC, as general partner ofLongitude Capital Associates, L.P. | 3/24/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Juliet Tammenoms Bakker, as managing member ofLongitude Capital Partners, LLC | 3/24/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Juliet Tammenoms Bakker | 3/24/2015 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Corcept Therapeutics Chart |
1 Month Corcept Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions